MorphoSys AG highlighted its expectations for upcoming Phase 3 data for its lead investigational product pelabresib in myelofibrosis during its quarterly results call with analysts on 10 August. Jean-Paul Kress, the chief executive, said the company is focused on completing the trial and getting it approved for marketing. Pelabresib is a small molecule drug which MorphoSys acquired with its takeover of Constellation Pharmaceuticals in 2021. If the data are positive and the drug is approved, pelabresib would be the company’s second wholly-owned drug on the market.
